key: cord-0717076-381ursa9
authors: Singh, Desh Deepak; Sharma, Anshul; Lee, Hae-Jeung; Yadav, Dharmendra K.
title: SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy
date: 2022-02-14
journal: Front Cell Infect Microbiol
DOI: 10.3389/fcimb.2022.839170
sha: 80aaacd3271e356dcdaaa36b38541fbdeb474965
doc_id: 717076
cord_uid: 381ursa9

Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level. Currently designated variants of concern (VOCs) are B.1.1.7, B1.351, P.1, B.1.617.2 variants and B.1.1.529. Possible options for VOC are urgently required as they carry mutations in the virus spike protein that allow them to spread more easily and cause more serious illness. The primary targets for most therapeutic methods against SARS-CoV-2 are the S (Spike) protein and RBD (Receptor-Binding Domain), which alter the binding to ACE2 (Angiotensin-Converting Enzyme 2). The most popular of these strategies involves the use of drug development targeting the RBD and the NTD (N-terminal domain) of the spike protein and multiple epitopes of the S protein. Various types of mutations have been observed in the RBDs of B.1.1.7, B1.351, P. and B.1.620. The incidence of RBD mutations increases the binding affinity to the ACE2 receptor. The high binding affinity of RBD and ACE2 has provided a structural basis for future evaluation of antibodies and drug development. Here we discuss the variants of SARS-CoV-2 and recent updates on the clinical evaluation of antibody-based treatment options. Presently, most of the antibody-based treatments have been effective in patients with SARS-CoV-2. However, there are still significant challenges in verifying independence, and the need for further clinical evaluation.

In December 2019, a non-specific case of respiratory disorder was reported in Wuhan, Hubei Province, Republic of China, and it was transmitted from human to human (Chen et al., 2020) . SARS-CoV-2, a coronavirus, is found in more than 200 nations and territories around the world. Coronaviruses are divided into four groups: Alpha (B.1.1.7), Beta (B1.351), Gamma (P.1), Delta (D.1) and Omicron (B.1.1.529). Human coronaviruses are Alpha and Beta coronaviruses (Singh et al., 2020a) . Bats are hosts to the largest number of viral genotypes of coronaviruses. Coronaviruses and their characteristics are shown in Table 1 (Singh et al., 2020b) . SARS-CoV-2 has genetic markers that have been linked to a potentially increased risk . New variants may elude medical treatments (Haimei, 2020) . Researchers from the field at a global level were notified of the emergence of a SARS-CoV-2 variant (Kar et al., 2021) . More than half of the total genomic sequencing of SARS-CoV-2 was carried out in the UK. Researchers from the field have identified eight global clades and classified them as S, O, L, V, G, GH, GR, and major lineages such as A, B, B.1, B.1.1, B.1.177, and B.1.1.7 have been identified (Koyama et al., 2020; Nayak et al., 2021) . The Omicron variant, known as lineage B.1.1.529, was proclaimed a variant of concern by the World Health Organization on November 26, 2021 (Callaway, 2021) . There are over 30 mutations in the variant, some of which are worrisome. The number of cases in line B.1.1.529 is increasing in all regions of South Africa. First discovered in South Africa, this new strain is now spread to more than 10 countries, including Canada, the United Kingdom, the Netherlands, Denmark and Australia. Concerns are growing around the world that the new strain will be more resistant to vaccine protection, prompting concerns that the pandemic and associated lockdown restrictions will last considerably longer than planned (Callaway, 2021) . Research on Omicron has begun around the globe, but it is not yet clear if this new COVID variant is more transmissible than other previous variants such as Alpha, Kappa, Delta, etc. (Callaway, 2021) . Mutations found in other VOCs include the N501Y mutation, which improves the binding of peplomer proteins to cell receptors, and the D614G mutation, which is thought to increase viral replication, both of which can increase viral infectivity. There is a sex. Others include the K417N and T478K mutations. These help the virus evade neutralizing antibodies produced by vaccination or previous infections. Researchers have discovered B.1.1.529 with 43 peplomer mutations in Rome (Callaway, 2021) . The SARS-CoV-2 protein recognizes host cells and is the primary target of the body's immune response. In November, cases increased rapidly in many countries, especially schools and adolescents. Variants have spike mutations that allow detection by genotyping tests that provide much faster results than genomic sequencing. The new variant of coronavirus reportedly has more than 30 mutations in the spike protein region and therefore has the potential to develop immune escape mechanisms. Most vaccines form antibodies against the spike protein, and so many mutations in the spike protein region may lead to a decreased efficacy of therapeutic options. The effectiveness of SARS-CoV-2 therapeutic developments is affected by the new emergent variants at the global level. Antibodies against the surface of the SARS-CoV-2 are commonly used to neutralize infection Diamond et al., 2021) . Most of the drugs are targeted towards the receptor binding domain (RBD) of the spike protein, and multiple epitopes of the S protein, as shown in Figure 1 .

As the protein SARS-CoV-2 and its RBD have been shown in vitro in cell culture, neutralization of the mAb against them effectively inhibits the binding of the virus to the host receptor, human angiotensin converting enzyme (hACE2), and thus is a major target of the mAb. Blocks viruses from invading cells (Yang et al., 2021) . Some antibodies bound outside the RBD may also neutralize the virus in vitro using an undefined mechanism. Some of the neutralizing antibodies passively protect SARS-CoV-2 infected animal models with high efficacy (Sette and Crotty, 2021) . Longitudinal studies evaluating the onset and duration of viral shedding and antibody response are needed in asymptomatic, mild, or severe patients. Here we discuss the emergence of variants of SARS-CoV-2 and the clinical evaluation of antibody-based treatment options. Presently, most of the antibody-based treatments have been effective in patients with SARS-CoV-2. However, there are still significant challenges in verifying independence, and a need for further clinical evaluation.

The appearance of novel SARS-CoV-2 variants has been observed all over the world, hampering the drug development process (Tables 2, 3) . New variants of current therapeutic options are required to maintain clinical efficacy (Sette and Crotty, 2021) . More clinical investigations are required for FDA approval against emerging variants. Bamlanivimab and etesevimab, will expected stagger in efforts to improvement full FDA approval given the antiviral resistance observed against B.1.351, P.1. and B.1.526 (Doggrell, 2021) . Optimization are required for its monoclonal antibody (mAb) to prove effective against the UK B.1.1.7 variant. Bamlanivimab have been observed less effective against most of the variants, but improved efficacy was observed in combination with etesevimab (Focosi et al., 2021) . The FDA has cancelled the EUA for bamlanivimab as monotherapy. Combo of casirivimab/ imdevimab has been observed more effective against new variants of SARS-CoV-2. Phase-III clinical trial data of casirivimab and imdevimab has been observed effective against new variants (Taylor et al., 2021) . FIGURE 1 | Schematic representation of receptor recognition and binding, spike receptor binding mechanism, receptor binding domain and receptor binding motifs. * g-genus is belong to Avian infectious bronchitis virus (IBV). 

Sotrovimab (VIR-7831), an antibody drug, is based on the entry of coronavirus into the body. Data from phase III clinical trials revealed that this medicine lowers the rate of hospitalization and death (Gupta et al., 2021) . In a recent study published in The New England Journal of Medicine, researchers theorized that a monoclonal antibody that neutralizes all SARS-CoV-2 would target a highly conserved epitope that would remain effective as SARS-CoV-2 mutates (Aschenbrenner, 2021) . In the phase III, multicenter, double-blind, placebo-controlled study, SARS-CoV-2 Monoclonal Antibody Efficacy Trial-Intent to Care Early (COMET-ICE), Researchers evaluated the impact of a single intravenous infusion of sotrovimab 500 mg on mild-to-moderate SARS-CoV-2 in high-risk, non-hospitalized patients (Cheng et al., 2021) . The risk of severe SARS-CoV-2 is higher in patients over 55 years old or in those who have diabetes, obesity, chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, or moderate-to-severe asthma.

One-time infusions of 500 mg of sotrovimab or placebo saline were given randomly to the patients (1:1). Primary outcomes were the percentage of patients who died or spent more than 24 hours in the hospital. A 72-day follow-up was averaged for the sotrovimab and placebo groups in the intention-to-treat population. Overall, 1% (3/291) of patients in the sotrovimab group and 7% (21/292) of patients in the placebo group had disease progression requiring hospitalization or death. In highrisk adults with symptomatic SARS-CoV-2, a single 500 mg dose of sotrovimab was found to minimize the probability of hospitalization or mortality by 85% (Aschenbrenner, 2021; Cheng et al., 2021; Gupta et al., 2021) . COMET-ICE, which compared monoclonal antibodies to SARS-CoV-2 and the subsequent variants, was apparent as evidence that sotrovimab neutralized SARS-CoV-2 and its variants. Sotrovimab has also shown efficacity against variant lineages B. 

Lenzilumab is an engineered anti-human granulocytemacrophage colony-stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat cytokine release syndrome preceding lung dysfunction and acute respiratory distress syndrome in serious SARS-CoV-2 infection cases (Bonaventura et al., 2020; Temesgen et al., 2021b) . Lenzilumab aced the Phase III LIVE-AIR trial (NCT04351152), a 54 relative enhancement in the liability of survival without ventilation (SWOV) vs. placebo (Temesgen et al., 2021a) . SWOV liability bettered by 92 in actors who entered both corticosteroids and Gilead Lores remdesivir (Veklury), and triple in cases under 85 times of age with a C-reactive protein position of< 150 mg/L. In the NIAID-patronized, placebo-controlled Phase II ACTIV-5 Big Effect Trial (NCT04583969), lenzilumab is being studied alone and in combination with Veklury to help and treat cytokine storms. Lenzilumab is also being researched for a variety of other indications. In May, Lenzilumab Humanigen submitted an application to the FDA for an emergency use authorization (EUA) for lenzilumab to treat SARS-CoV-2 patients hospitalized. Lenzilumab has been proven to be effective against the B. 

Bamlanivimab (LY-CoV555) is a recombinant human IgG1 mAb, that prevents viral attachment and penetration into human cells while also neutralizing the virus (Kuritzkes, 2021) . The Journal of the American Medical Association released the results of a Phase 3 study of bamlanivimab among residents and staff in long-term care facilities (NCT04497987) (Dougan et al., 2021) . The emergency use of LY-CoV555 700 mg in combination with etesevimab (LY-CoV016) 1400 mg has been expanded by the FDA to include post-exposure prophylaxis (PEP) to prevent SARS-CoV-2 infection or symptomatic SARS-CoV-2 infection ( Table 4 ). These antibodies, which have been demonstrated to be effective against the extremely contagious Delta variant, can now be used to protect some of the most vulnerable people who are exposed to the virus with this expanded authorization (Dougan et al., 2021; Nathan et al., 2021) . Bamlanivimab and etesevimab jointly retain neutralizing activity against the Alpha and Delta forms, according to pseudovirus and authentic virus studies. Because both the P.1 and B.1.351 variants exhibit reduced sensitivity to bamlanivimab and etesevimab, the distribution of bamlanivimab with etesevimab has been halted in the United States. However, in areas with low prevalence of these and other variants that have lowered susceptibility to bamlanivimab and etesevimab, the distribution of the agents has been reinstated in states (Dougan et al., 2021; Nathan et al., 2021) .

AstraZeneca has developed two antibody cocktails known as AZD7442, which have been shown to have potent responses against SARS-CoV-2 (Mahase, 2021) . In a clinical trial including 5000 volunteers, AZD7442 was reported to be 77% effective in a patient with SARS-CoV-2. AstraZeneca reported the results in August 2021 (Dong et al., 2021) . That continuity would make it especially useful to immunocompromised cases who do not get important protection from vaccines (Dong et al., 2021) . The federal government has reached an agreement with the company to order up to 700,000 doses of the treatment this year, but it will first need to be authorized (Dong et al., 2021) . AZD7442 has been shown to be effective against the variant lineages B. (Yang et al., 2020) . Preliminary in vitro evidence suggests continued antiviral activity against commonly circulating variants from the U.K. and South Africa (Yang et al., 2020) . A phase 1 study completed dosing and follow-up by providing safety profiles and human pharmacokinetic profiles for two separate antibodies (Baral et al., 2021) . Combination therapy consisting of BRII196 and BRII198 was originally investigated in the April 2021 NIAID ACTIV3 study (NCT04501978) in inpatients. However, it did not meet the pre-determined performance criteria required for Phase 3 entry. As part of an ongoing NIH ACTIV2 trial (NCT04518410), a mixture of BRII196 and BRII198 antibodies is in phase 3 clinical trials (Baral et al., 2021) .

CERC002 is a fully human monoclonal antibody against LIGHT or TNFSF14 (a member of the tumor necrosis factor superfamily 14) (Haljasmägi et al., 2020) . He is currently being tested for SARS-CoV-2 ARDS due to Crohn's disease and cytokine storm. This study will evaluate the efficacy and safety of CERC002 in patients with severe SARS-CoV-2 for 28 days as a single dose in addition to standard treatment (Perlin et al., 2020) . CERC002 increased survival by day 28 and the number of people without respiratory failure in hospitalized patients with mild to moderate SARS-CoV-2-associated pneumonia (ARDS) compared to placebo (83.9% versus 64.5%, P = 0.044). Efficacy was highest in the predefined patient subgroup 60 years and older (76.5% versus 47.1%, P = 0.042), which is the population most vulnerable to serious complications and death from SARS-CoV-2 infection (Rodriguez-Perez et al., 2021) . There was an approximately 50% reduction in mortality with CERC002 compared to placebo on both the first 28 days and 60 days (7.7% vs. 14.3% at 28 days and 10.8% vs. 22.5% at 60 days) (Rodriguez-Perez et al., 2021) . In the final efficacy data for the phase 2 study (NCT04412057), Cerecor showed that more COVID19 patients with acute respiratory distress who received a single dose of CERC002 instead of placebo were alive and not experiencing dyspnea during the 28-day study period. The efficacy was highest in patients over the age of 60 who frequently suffered from other inflammatory diseases.

SAB185 is a therapeutic candidate for neutralizing polyclonal antibodies to treat non-hospitalized mild-to-moderate SARS-CoV-2 patients . The candidate is being evaluated in the ACTIV2 trial conducted by NIAID, which is part of the NIH in collaboration with the AIDS Clinical Trial Group. SAB185 is a fully human polyclonal candidate antibody designed to confer passive immunity. The first patient in the NIAID-sponsored Phase II/III ACTIV2 study (NCT04518410) received a dose of SAB185 in April after a previous trial demonstrated the safety of an antibody with a half-life of 25-28 days. SAB185, the second drug to enter Phase 3 and the first candidate for polyclonal antibody therapy in ACTIV2, is evaluating several research drugs to treat early symptoms of SARS-CoV-2 in non-hospitalized individuals . SAB185 was transferred to Phase II as part of the Phase III ACTIV2 trial after meeting all required termination criteria. SAB185 effectively neutralizes viruses containing SARS-CoV-2 spikes with S477N, E484K, and N501Y mutations. This virus has been associated with the outbreak and outbreak of SARS-CoV-2 in several countries, leading to antibody resistance . WHO has identified several VOCs with mutations in the spike protein SAB185 was tested in BSL2 medium using a lentiviral pseudo virus experiment containing a stable 293T cell line expressing human ACE2 and TMPRSS2. Data collected from 221 patients in study SG016 Phase II (NCT04385095) showed that 33 patients with severe or severe dyspnoea and received SNG001 were 3.41 times more likely to recover than patients who received placebo. In vitro data show that SNG001 exhibits antiviral activity against two strains of COVID19, B.1.1.7 and B.1.351 (Saeed et al., 2020) . The results show that SAB185 retained neutralizing ability against several strains of SARS-CoV-2-like virus, including delta, kappa and lambda variants, which is displacing other VOCs in many countries and regions around the world .

In outpatients with mild to moderate SARS-CoV-2, a placebocontrolled randomized trial looked at different dosages of casirivimab plus imdevimab . FDA simplified the EUA for casirivimab plus imdevimab, reducing the approved dose for single intravenous infusion from casirivimab 1200 mg plus imdevimab 1200 mg to casirivimab 600 mg plus imdevimab 600 mg (NCT04425629) (Deeks, 2021; Razonable et al., 2021) . Participants included were 18 years of age or older, tested positive for SARS-CoV-2, and had at least one risk factor for developing severe SARS-CoV-2. Results showed a 2.2% overall reduction and a 70% reduction in hospitalizations or deaths when taking casirivimab 600 mg plus imdevimab 600 mg. These results are similar to those observed with an intravenous infusion of casirivirab 1200 mg plus imdevimab 1200 mg, which resulted in an absolute 3.3°reduction in hospitalizations or deaths and a 71% relative decrease (NCT04519437), also found to be active against delta variant (O'Brien et al., 2021) .

Regdanvimab (CTP59) blocks the RBD interaction region of ACE2 in one direction. Therefore, CTP59 has the potential to be a promising treatment candidate for COVID19 . In September 2021, the Korean Ministry of Food and Drugs (MFDS) treated patients over the age of 50 with mild COVID19 and approved Regdanvimab in adults with at least one underlying disease and moderate disease symptoms. This approval is based on the first part of a global Phase 2/3 study showing a 54% reduction in progression to severe COVID 19 in patients with mild to moderate symptoms and a 68% reduction in patients over 50 years of age. In October 2021, the European Medicines Agency (EMA) began considering a marketing authorization application for this mAb for the treatment of adults with COVID19 who do not require additional oxygen therapy and are at high risk of developing severe COVID19. Did. The dose of Regdanvimab is a single intravenous infusion of 40 mg/kg (Syed, 2021) . A double-blind, placebo-controlled, randomized, phase II study, BLAZE4 (NCT04634409), found the efficacy of other mAbs, including bumlanivimab (700 mg) and sotrovimab (500 mg), for the treatment of symptoms. We are evaluating safety. Low-risk, non-hospitalized COVID 19 patients. Preliminary results showed that bablanivimab/ sotrovimab (700/500 mg) showed 70% (p <0> 5.27; day 7 cycle threshold <27.5 vs. placebo) (Syed, 2021) . A recent study compared and evaluated all published studies investigating SARS-CoV-2 neutralized mAbs (single or combined vs. active comparator, placebo, or no intervention) for the treatment of patients with COVID19 and "to the evidence. I evaluated "trust". About preventive use). The authors conclude that the available evidence is insufficient to draw meaningful conclusions about treatment with SARS-CoV-2-neutralized mAbs Syed, 2021) 

Interferons are produced by our cells naturally against viral infection. Interferons have strong effects on the immune system, stimulating it to attack invaders while also inhibiting it to avoid damaging the body's own tissues (Felgenhauer et al., 2020) . Injecting synthetic interferons is now a standard treatment for several immune disorders. Interferon's approach to storming our bodies, enthused researchers to see whether an improvement in interferon might help in the early-stage infection of patients with SARS-CoV-2 (Della-Torre et al., 2020). Preliminary investigations in cells and mice have yielded reassuring results that have led to clinical trials (Murugan et al., 2021) . On October 20, 2021, Synairgen proclaimed that the drug was moving forward into a Phase III clinical trial in mild-to -moderate SARS-CoV-2 patients. Sarilumab and tocilizumab are two classes of FDA-approved IL-6 inhibitors ( Table 5) .

Sarilumab is a monoclonal antibody that has been evaluated for off-label usage in the treatment of SARS-CoV-2. It binds to both membrane-bound and soluble IL-6 receptors with significant affinity (Gremese et al., 2020) . Sarilumab 400 mg is reconstituted in 100 cc of 0.9% NaCl and administered as an hour long IV infusion. The SQ formulation was utilized to produce the IV infusion in the randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia (REMAP-CAP) trial. In a revised report of the REMAP-CAP trial, sarilumab and tocilizumab were equally effective in improving survival and reducing time to organ supply. Patients receiving dexamethasone and sarilumab had lower mortality than patients in the control group who received dexamethasone plus placebo, had shorter time to discharge from the ICU, and had more days without organ support (https://www. covid19treatmentguidelines.nih.gov/). The combination of sarilumab and dexamethasone (n = 483) is 99% and 98% likely to be inferior to tocilizumab (n = 943) with dexamethasone in terms of days without organ support and days of death, respectively. REMAPCAP studies have shown that tocilizumab and sarilumab show similar efficacy in treating inpatients with COVID 19, but the panel recommends the use of sarilumab only if tocilizumab is not available or applicable. A single 400 mg dose of sarilumab for injection of SQ was reconstituted with normal saline (50 or 100 ml) and intravenously over 1 hour in the REMAPCAP study (https://www.covid19treatmentguidelines.nih.gov/). It was administered as an internal infusion. Recommendations for COVID19 treatment for the IL6 inhibitors sarilumab and tocilizumab in hospitalized patients requiring oxygenation, high flow oxygen, non-invasive ventilation or invasive ventilation (https://www.covid19treatmentguidelines.nih.gov/).

Tocilizumab is a monoclonal antibody against interleukin-6 receptor-alpha that is used for inflammatory diseases, improved consequences have been observed in patients with severe SARS-CoV-2 pneumonia ( Figure 2 ) (Samaee et al., 2020; Stone et al., 2020) . Tocilizumab showed a slower progression of the disease, as well as a sharp decrease in temperature and mechanical ventilation. In the STOPCOVID study, tofacitinib was associated with a lower risk of respiratory failure and death (hazard ratio 0.63, 95% CI 0.41-0.97). Within 28 days, 5.5% of patients in the placebo group (n = 145) and 2.8% of patients in the tofacitinib group (n = 144) (hazard rate 0.49, 95% CI, 0.15-1.63) had all-cause mortality. About 80% of participants in each group also received corticosteroids. Serious adverse events occurred in 14.2% of participants in the tofacitinib group and 12.0% of participants in the placebo group (Hermine et al., 2021) . STOPCOVID study found that tofacitinib plus steroids improved outcomes in hospitalized SARS-CoV-2 patients.

EUA of mAbs against SARS-CoV-2 were due to the context declared emergency without available alternatives (Aschenbrenner, 2021) . EUA is a mechanism used by the FDA to facilitate making products available quickly during a public health emergency; this differs from FDA approval, which is an independent, scientifically reviewed approval for medical products, drugs, and vaccines, based on substantial clinical data and evidence (Bonaventura et al., 2020; Temesgen et al., 2021b) . The use of SARS-CoV-2 neutralizing antibodies has not been authorized by the FDA-EUAs for patient hospitalized for SARS-CoV-2 or for those requiring oxygen therapy due to SARS-CoV-2 or patient who are on chronic oxygen therapy due to an underlying condition not related to SARS-CoV-2 that require an increase in oxygen flow rate from baseline (Taylor et al., 2021) . Furthermore, the FDA EUAs indicates that all approved mAbs may be associated with worse clinical outcomes when administered to hospitalized patients with SARS-CoV-2 requiring high flow oxygen or mechanical ventilation. In the bamlanivimab plus etesevimab arm, the trial showed a 4.8% absolute reduction and a 70% relative reduction in hospitalizations due to SARS-CoV-2 or deaths from any cause. The authorized dosage of 700/1400 mg lower than the dosage tested in BLAZE-1 is based on initial results (Dougan et al., 2021) . Sotrovimab is supported by the results of an interim analysis of an ongoing multicenter, double-blind, Phase 3 COMETICE trial (NCT04545060) (Gupta et al., 2021) . The main limitation of these studies is the reported result of environmental heterogeneity, making it difficult to make appropriate comparisons are shown in Table 6 .

Personalized medicine plays an important role in the treatment of 19 cases of severe COVID (Khoury et al., 2020; Toor et al., 2021) . The idea of cell-based treatment has not been accepted by some scientific communities due to some concerns about the lack of satisfactory clinical research. Nonetheless, MSC and its clinical results show the safety and efficacy of this therapeutic approach in some diseases, especially immune-inflammatory and some incurable diseases (Figure 3 ) (Khoury et al., 2020; Li et al., 2020 (Toor et al., 2021) . Moreover, as long as the MSC is clinical and time consuming and costly, the MSC remains suspicious.

In mRNA vaccines, single-strand RNA (ssRNA) and doublestrand RNA (dsRNA) is recognized by endosomes and cytosols. which is an important part of the natural immune response to the virus (Park et al., 2021) . Endosomal Toll-like receptors bind to endosome ssRNA and inflammasome components such as MDA5, RIGI, NOD2 and PKR. Inflammasome components activate the production of interferons and inflammation Mediators. Current vaccines contain purified in vitro transcriptional single-stranded mRNA with nucleotides modified to reduce binding to TLRs and immune sensors, thus inhibiting overproduction of type I interferon and cell translation. Functions are limited. LNP carriers further protect mRNA, target delivery to lymphatic vessels, and promote protein translation in lymphatic vessels. Preclinical and early results from human studies show that both vaccines produce anti-S protein IgG and virus-specific neutralizing antibody responses months after vaccination, but T cell data not been completely elucidated (Teijaro and Farber, 2021) .

Vaccines are the most effective way for most people to protect themselves from COVID 19. For the past two years, as the only possible solution to the further spread and recurrence of SARS-CoV-2, the entire scientific community has focused on researching, developing, and ultimately manufacturing safe and effective vaccines (Liz et al., 2020; Nathan et al., 2021) . Vaccine development can take years or even decades, but aggressive efforts to screen multiple COVID19 vaccine candidates simultaneously can significantly reduce the overall time required for the development process. MAb is currently an alternative preventive route for COVID19 and may provide short-term prophylaxis to those who have not yet been vaccinated or who do not respond appropriately to vaccination, such as immunocompromised patients. In addition, mAb may be useful if the circulating mutant virus is not adequately covered by vaccination protection (Dong et al., 2021) . The PROVENT study was conducted on subjects who would benefit from long-acting antibody prevention because of an increased risk of inadequate response to active immunization or an increased risk of SARS-CoV-2 infection.

Monitoring resistance to mAbs among new mutants is important in deciding whether to discontinue some of the newly developed mAbs or investigate different combinations. Mutations in SARS-CoV-2 peplomer and clinical mAb resistance profile in VOC It is summarized in Table 7 .

The idea behind the development of SARS-CoV-2 Abs was that enhanced neutralization efficacy would equate to more therapeutic benefit. Development of deactivating cross-reactive human Abs to conserved epitopes on SARS-CoV-2 that can impede infection by emerging SARS-CoV-2 outbreaks. Identification of such conserved epitopes is also essential for the layout of broadly reactive vaccines to thwart future SARSrelated coronavirus infections. Monoclonal antibodies and neutralizing antibodies targeting SARS-CoV-2 virus antigens have shown promising results in treating SARS-CoV-2 patients and controlling disease progression. To improve treatment options, an effective understanding of the competent therapeutic characteristics of antibody-based treatments, primarily neutralizing monoclonal antibodies and establishing their therapeutic or prophylactic applications against SARS-CoV-2, is required. In addition, among other potential therapeutic strategies, personalized viral-specific T cells can be generated to prevent infections among populations at risk and/or treat SARS-CoV-2 infections. 

DDS thanks Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India, and AS, H-JL, and DKY thank Gachon University, Republic of Korea, for providing the necessary computational and journal subscriptions for the needed literature search. The authors appreciate Biorender.com's graphics assistance. 

Another Monoclonal Antibody Granted EUA to Treat SARS-COV-2. AJN

COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines (Basel)

Treatment and Prevention Strategies for the COVID 19 Pandemic: A Review of Immunotherapeutic Approaches for Neutralizing SARS-CoV-2

Breakthrough SARS-COV-2 and Casirivimab-Imdevimab Treatment During a SARS-CoV-2 B. 1.617. 2 (Delta) Surge

Targeting GM-CSF in SARS-COV-2 Pneumonia: Rationale and Strategies

Heavily Mutated Coronavirus Variant Puts Scientists on Alert

Efficacy and Safety of Current Medications for Treating Severe and non-Severe SARS-COV-2 Patients: An Updated Network Meta-Analysis of Randomized Placebo-Controlled Trials

Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study

Casirivimab/Imdevimab: First Approval

Interleukin-6 Blockade With Sarilumab in Severe SARS-COV-2 Pneumonia With Systemic Hyperinflammation: An Open-Label Cohort Study

Vivo Monoclonal Antibody Efficacy Against SARS-CoV-2 Variant Strains. Res. Square. rs.3.rs-448370

Do We Need Bamlanivimab? Is Etesevimab a Key to Treating SARS-CoV-2? Expert Opin

Genetic and Structural Basis for SARS-CoV-2 Variant Neutralization by a Two-Antibody Cocktail

Bamlanivimab Plus Etesevimab in Mild or Moderate SARS-CoV-2. New Engl

Inhibition of SARS-CoV-2 by Type I and Type III Interferons

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Sarilumab Use in Severe SARS-CoV-2 Pneumonia

Early Treatment for SARS-CoV-2 With SARS-CoV-2 Neutralizing Antibody Sotrovimab

Pathogenesis and Treatment Strategies of SARS-COV-2-Related Hypercoagulant and Thrombotic Complications

Longitudinal Proteomic Profiling Reveals Increased Early Inflammation and Sustained Apoptosis Proteins in Severe SARS-COV-2

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With SARS-COV-2 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Second Wave of SARS-COV-2 Pandemic in India: Barriers to Effective Governmental Response

Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to SARS-COV-2

A Therapeutic Neutralizing Antibody Targeting Receptor Binding Domain of SARS-CoV

Spike Protein

Variant Analysis of SARS-CoV-2 Genomes

Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH

Bamlanivimab for Prevention of SARS-COV-2

Stem Cell Therapy for SARS-COV-2, ARDS and Pulmonary Fibrosis

Human Immunoglobulin From Transchromosomic Bovines Hyperimmunized With SARS-CoV-2 Spike Antigen Efficiently Neutralizes Viral Variants

Covid-19: AstraZeneca Says Its Antibody Drug AZD7442 Is Effective For Preventing and Reducing Severe Illness

SARS-COV-2: A Review of Newly Formed Viral Clades, Pathophysiology, Therapeutic Strategies and Current Vaccination Tasks

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2

Host Response to SARS-CoV-2and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases

Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. medRxiv. preprint. Server. Health Sci

mRNA Vaccines for SARS-COV-2: What, Why and How

Levels of the TNF-Related Cytokine Light Increase in Hospitalized SARS-COV-2 Patients With Cytokine Release Syndrome and ARDS

Monoclonal Antibodies Against SARS-CoV-2: Current Scenario and Future Perspectives

Casirivimab-Imdevimab Treatment is Associated With Reduced Rates of Hospitalization Among High-Risk Patients With Mild to Moderate Coronavirus Disease-19

Antibody-Based Therapy for SARS-CoV-2

Autoantibodies Against ACE2 and Angiotensin Type-1 Receptors Increase Severity of SARS-COV-2

Identification of Persuasive Antiviral Natural Compounds for SARS-COV-2 by Targeting Endoribonuclease NSP15: A Structural

Tocilizumab for Treatment Patients With SARS-COV-2: Recommended Medication for Novel Disease

Adaptive Immunity to SARS-CoV-2 and SARS-COV-2

Immunopathology, Host-Virus Genome Interactions, and Effective Vaccine Development in SARS-CoV-2

Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. Front

SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines

Efficacy of Tocilizumab in Patients Hospitalized With SARS-CoV-2

Regdanvimab: First Approval

Neutralizing Monoclonal Antibodies for Treatment of SARS-COV-2

SARS-COV-2 Vaccines: Modes of Immune Activation and Future Challenges

Lenzilumab Efficacy and Safety In Newly Hospitalized Sars-Cov-2 Subjects: Results from the Live-Air Phase 3 Randomized Double-Blind Placebo-Controlled Trial. medRxiv

Reply -Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease

T-Cell Responses and Therapies Against SARS-CoV-2 Infection

A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection

Human Neutralizing Antibodies Against SARS-CoV-2 Require Intact Fc Effector Functions for Optimal Therapeutic Protection

Current Potential Therapeutic Approaches Against SARS-CoV-2: A Review

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain

SARS-COV-2 Antibody Therapeutics Tracker: A Global Online Database of Antibody Therapeutics for the Prevention and Treatment of SARS-COV-2

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.